美国老年人新冠与流感疫苗联合接种情况
研究描述2021年和2022年9-11月社区居住的≥66岁医保受益人接种mRNA新冠加强针后流感疫苗接种及联合接种情况;联合接种比例从11.1%升至36.5%,总体流感疫苗接种率高但联合接种率低。
要点
- 2021年周期联合接种11.1%,2022年周期升至36.5%。
- 2022年周期痴呆者联合接种可能性较高(aOR=1.31)。
- 2022年周期农村县居民联合接种可能性较高(aOR=1.19)。
核心结论
- 接种新冠疫苗的医保受益人中流感疫苗接种率高,但两种疫苗联合接种率低;未来工作应探索决定联合接种差异的因素。
研究设计与样本
- 描述性重复横断面研究,纳入2021年9月1日至11月30日和2022年9月1日至11月30日接种mRNA新冠加强针的≥66岁社区居住医保受益人。
主要发现
- 接种新冠疫苗者中,第一周期78.8%(N=6,292,777)和第二周期89.1%(N=4,757,501)在研究期间某时点接种了流感疫苗。
- 联合接种比例从第一周期11.1%升至第二周期36.5%。
- 第二周期痴呆者联合接种aOR=1.31(99%CI=1.29-1.32),农村县居民aOR=1.19(99%CI=1.17-1.20),癌症患者aOR=0.90(99%CI=0.89-0.91)。
- 非白人和农村个体流感疫苗接种率较低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Coadministering COVID-19 and influenza vaccines is recommended by public health authorities and intended to improve uptake and convenience; however, the extent of vaccine coadministration is largely unknown. Investigations into COVID-19 and influenza vaccine coadministration are needed to describe compliance with newer recommendations and to identify potential gaps in the implementation of coadministration. METHODS: A descriptive, repeated cross-sectional study between September 1, 2021 to November 30, 2021 (Period 1) and September 1, 2022 to November 30, 2022 (Period 2) was conducted. This study included community-dwelling Medicare beneficiaries ≥ 66 years who received an mRNA COVID-19 booster vaccine in Periods 1 and 2. The outcome was an influenza vaccine administered on the same day as the COVID-19 vaccine. Adjusted ORs and 99% CIs were estimated using logistic regression to describe the association between beneficiaries' characteristics and vaccine coadministration. Statistical analysis was performed in 2023. RESULTS: Among beneficiaries who received a COVID-19 vaccine, 78.8% in Period 1 (N=6,292,777) and 89.1% in Period 2 (N=4,757,501), received an influenza vaccine at some point during the study period (i.e., before, after, or on the same day as their COVID-19 vaccine), though rates were lower in non-White and rural individuals. Vaccine coadministration increased from 11.1% to 36.5% between periods. Beneficiaries with dementia (aORPeriod 2=1.31; 99%CI=1.29-1.32) and in rural counties (aORPeriod 2=1.19; 99%CI=1.17-1.20) were more likely to receive coadministered vaccines, while those with cancer (aORPeriod 2=0.90; 99%CI=0.89-0.91) were less likely. CONCLUSIONS: Among Medicare beneficiaries vaccinated against COVID-19, influenza vaccination was high, but coadministration of the 2 vaccines was low. Future work should explore which factors explain variation in the decision to receive coadministered vaccines.
引用
- Harris DA, Chachlani P, Hayes KN, et al. COVID-19 and Influenza Vaccine Coadministration Among Older U.S. Adults. Am J Prev Med. 2024. PMID: 38401746. doi:10.1016/j.amepre.2024.02.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。